SY

Shenjun Yan, PhD

Chairman of China Tianying Group (likely Investor/Board Member)

RapaFusyn Pharmaceuticals

RapaFusyn Pharmaceuticals Pipeline

DrugIndicationPhase
ENT1 InhibitorAcute Kidney InjuryPreclinical
ONC-003OncologyPreclinical
ONC-005OncologyPreclinical
ONC-006OncologyPreclinical
ONC-001OncologyPreclinical
IMM-001Immunology & InflammationPreclinical
IMM-002Immunology & InflammationPreclinical
IMM-003Immunology & InflammationPreclinical